We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

54 hedge funds and large institutions have $12.5M invested in VYNE Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

265% more call options, than puts

Call options by funds: $95K | Put options by funds: $26K

0.29% less ownership

Funds ownership: 1.56% → 1.27% (-0.29%)

16% less funds holding

Funds holding: 64 → 54 (-10)

38% less capital invested

Capital invested by funds: $20.1M → $12.5M (-$7.62M)

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

Holders
54
Holders Change
-10
Holders Change %
-15.63%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
8
Reduced
17
Closed
19
Calls
$95K
Puts
$26K
Net Calls
+$69K
Net Calls Change
-$39K

Top Buyers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
+$1.73M
2
Marshall Wace
Marshall Wace
United Kingdom
+$197K
3
GCP
GSA Capital Partners
United Kingdom
+$149K
4
Goldman Sachs
Goldman Sachs
New York
+$87.8K
5
VF
Virtu Financial
New York
+$79.8K

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$2.12M
2
6CM
683 Capital Management
New York
-$994K
3
Renaissance Technologies
Renaissance Technologies
New York
-$406K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$227K
5
CM
CM Management
Florida
-$200K
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
51
CM Management
Florida
– -$200K -7,986 Closed
Two Sigma Investments
52
Two Sigma Investments
New York
– -$113K -4,516 Closed
BCV
53
Banque Cantonale Vaudoise
Switzerland
– -$95.4K -4,444 Closed
HF
54
HRT Financial
New York
– -$108K -4,334 Closed
ECM
55
ExodusPoint Capital Management
New York
– -$68K -2,701 Closed
LP
56
LMR Partners
United Kingdom
– -$27K -1,098 Closed
BPA
57
Beacon Pointe Advisors
California
– -$22K -889 Closed
PTP
58
Platform Technology Partners
New York
– -$20K -803 Closed
ProShare Advisors
59
ProShare Advisors
Maryland
– -$15K -611 Closed
Principal Financial Group
60
Principal Financial Group
Iowa
– -$14K -567 Closed
GWS
61
Glassman Wealth Services
Virginia
– -$8K -306 Closed
BWA
62
BDO Wealth Advisors
Florida
– -$7K -278 Closed
UBS Group
63
UBS Group
Switzerland
– -$4.53K -211 -94%
JP Morgan Chase
64
JP Morgan Chase
New York
– -$4.31K -201 -96%
Citigroup
65
Citigroup
New York
– -$4K -161 Closed
TWA
66
TCI Wealth Advisors
Arizona
– -$4K -153 Closed
PCM
67
Penserra Capital Management
California
– -$1K -66 Closed
EWM
68
Edge Wealth Management
New York
– -$1K – –
1 2
3

VYNE Hedge Fund Activity: Q4 2021 in Review

54 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2021, worth a combined $12.5M — down 38% from $20.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VYNE and 10 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was DSC Advisors, adding an estimated $1.73M. The largest seller was Franklin Resources, cutting an estimated $2.12M.

  • 54 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2021, down from 64 in Q3 2021.
  • Funds reported $12.5M of VYNE Therapeutics stock for Q4 2021, down 38% quarter-over-quarter.
  • 10 funds opened new VYNE Therapeutics positions in Q4 2021 and 19 closed out, a net change of -9 holders.
  • The largest VYNE Therapeutics buyer in Q4 2021 was DSC Advisors, an estimated $1.73M added.
  • The largest VYNE Therapeutics seller in Q4 2021 was Franklin Resources, an estimated $2.12M sold.

Based on aggregated 13F filings for Q4 2021.